

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/561,780
Filing Date	§ 371 Date: July 2, 2007
First Named Inventor	KOLOSSOV, Eugen
Art Unit	1632
Examiner Name	NOBLE, Marcia Stephens
Attorney Docket Number	2590.0030002/EJH/SAC

Sheet	1	of	1
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

791030v1


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.N./

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Equivalent of Form PTO/SB/08b (01-08)

Approved for use through 02/29/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/561,780
				Filing Date	§ 371 Date: July 2, 2007
				First Named Inventor	KOLOSSOV, Eugen
				Art Unit	1632
				Examiner Name	NOBLE, Marcia Stephens
Sheet	1	of	1	Attorney Docket Number	2590.0030002/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	KETTENHOFEN, R., <i>et al.</i> , "Transgenic Murine Embryonic Stem Cells as an <i>in vitro</i> Model for Developmental Toxicity - An Alternative to the Gold Standard," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> 365, Suppl. 1:R154, Springer Verlag, Abstract Number 601 (March 2002)	
	NPL2	KOLOSSOV, E., <i>et al.</i> , "Transplantation of the Cardiomyocytes Selected from Transgenically Designed ES cells: Quality Control and Engrafting Support of Fibroblasts," <i>Tissue Engineering</i> 9:853-854, Mary Ann Liebert, Inc., Abstract Number 230 (August 2003)	
	NPL3	MUMMERY, C., <i>et al.</i> , "Differentiation of Human Embryonic Stem Cells to Cardiomyocytes: Role of Coculture With Visceral Endoderm-Like Cells," <i>Circulation</i> 107:2733-2740, Lippincott Williams and Wilkins (June 2003)	
	NPL4	MÜLLER, M., <i>et al.</i> , "Selection of ventricular-like cardiomyocytes from ES cells <i>in vitro</i> ," <i>FASEB J.</i> 14:2540-2548, The Federation of American Societies for Experimental Biology (2000)	
	NPL5	SACHINIDIS, A., <i>et al.</i> , "Cardiac specific differentiation of mouse embryonic stem cells," <i>Cardiovascular Research</i> 58:278-291, Elsevier Science B.V. (May 2003)	
	NPL6	SPIELMANN, H., <i>et al.</i> , "The use of transgenic embryonic stem (ES) cells and molecular markers of differentiation for improving the embryonic stem cell test (EST)," <i>Congenit. Anom.</i> 40:S8-S18, Japanese Teratology Society (2000)	
	NPL7	International Search Report for International Application No. PCT/EP2004/006698, mailed on February 1, 2005, European Patent Office, Netherlands	
	NPL8	U.S. Application No. 10/594,177 (U.S. National Phase of PCT/EP04/07529), inventors Ehlich, <i>et al.</i> , I.A. filed July 8, 2004 (NOT YET PUBLISHED)	
	NPL9	U.S. Application No. 11/547,871 (U.S. National Phase of PCT/EP05/03662), inventors Bohlen, <i>et al.</i> , I.A. filed April 7, 2005 (NOT YET PUBLISHED)	
	NPL10	U.S. Application No. 11/596,262 (U.S. National Phase of PCT/EP05/05087), inventors Bohlen, <i>et al.</i> , I.A. filed May 11, 2005 (NOT YET PUBLISHED)	

791029v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.N./

Examiner Signature	Marcia Noble <small>Examiner, U.S. Patent and Trademark Office 1500 ... ... ...</small>	Date Considered	07/14/2009
--------------------	--	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.